Background: UII is elevated in patients with heart failure; however its role in acute
Introduction
Acute myocardial Infarction (AMI) is a leading cause of mortality and morbidity. Recent advances in the treatment of AMI have improved patient survival. However, despite this there is still an appreciable mortality associated with this condition. The challenge remains to try and identify those patients who are deemed to be at high risk of adverse clinical outcome (ACO).
Circulating natriuretic peptides certainly provide some information with regard to prognosis following AMI [1, 2] . However a multimarker approach may be more informative [3] . We investigated a novel cardiovascular peptide called urotensin II (UII) with homology to the teleost fish hormone [4] . This cyclic undecapeptide is the ligand for an orphan G protein receptor (GPR14), and both peptide and receptors are found within the cardiovascular system [5] . UII has potent vasoactive properties, which appear to be variable and dependent on the vascular bed. UII causes potent vasoconstriction in rat thoracic aorta [4] , whereas it caused potent vasodilatation in human pulmonary vasculature and abdominal resistance vessels [6] .
UII has a cardiostimulatory action as it mediates a positive inotropic effect in human atrium [7] . Recently it has been found to be elevated in heart failure irrespective of age, sex, or NYHA class which suggests a pathophysiological role for this peptide in this disease state [8] .
The aims of the study were to establish the secretory patterns in the acute phase of AMI and to investigate whether UII levels could be used as a prognostic marker in combination with N terminal proB type natriuretic peptide (NT-BNP) in AMI patients.
Materials and Methods

Study population
We studied 129 patients admitted to the Coronary Care Unit of Leicester Royal Infirmary. The study complied with the Declaration of Helsinki, was approved by the local ethics committee and written informed consent was obtained from patients. AMI was defined at presentation with at least two of three standard criteria, i.e. appropriate symptoms, acute ECG changes of infarction (ST elevation or depression, new left bundle branch block) and a rise in troponin T above the 99 th centile for our population. AMI was sub categorised into ST segment elevation myocardial infarction (STEMI) or non-ST segment myocardial infarction (NSTEMI). Control subjects were age and gender matched and recruited from University of Leicester.
Plasma Samples
Serial blood measurements were made at 0-24, 25-48, 49-72, 73-96, 97-120 hr after onset of chest pain for determination of plasma UII and N-BNP. After 15 minutes bed rest, 20mL blood was collected into tubes containing EDTA and aprotinin. Plasma was stored at -70°C until assayed and all analysis was done in a single batch.
Echocardiography
Transthoracic echocardiography was performed in patients using a Sonos 5500 instrument was calculated using the biplane method of discs formula [9] .
NT-BNP Assay
Our NT-BNP assay was based on a non-competitive assay [10] . Sheep antibodies were raised to the N-terminal of human NT-BNP and monoclonal mouse antibodies were raised to the Cterminal. The N-terminal IgG was affinity-purified and biotinylated. Samples or NT-BNP standards were incubated in C-terminal IgG-coated wells with the biotinylated antibody for 24 hours at 4°C. Detection was with methyl-acridinium ester (MAE)-labelled streptavidin [11] .
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The lower limit of detection was 0.3 fmol/mL. There was no cross reactivity with atrial natriuretic peptide, BNP, or C-type natriuretic peptide.
Urotensin II Assay
Stored plasma samples were extracted using C 18 Sep-Pak column cartridges and redissolved in assay buffer for measurement of UII Antibody specific for UII was obtained from Bachem, St.
Helens, Merseyside, U.K. Biotinylated UII purified on reverse-phase high pressure liquid chromatography served as the tracer. A competitive assay with C 18 extracts of plasma was utilized, incubating 50 ng of the antibody with extracts or standards in assay buffer [11] . After 24 hours of incubation at 4°C, biotinylated UII tracer was added (250 fmol/well).
Immunoprecipitates were recovered in anti-rabbit IgG-coated ELISA plates. After washes and incubation with streptavidin-MAE, chemiluminescence was elicited as described [11] . The lower limit of detection was 0.29 fmol/mL.
End points
We assessed the value of both UII and NT-BNP for the prediction of mortality. We used a combined endpoint consisting of mortality, reinfarction, need for urgent revascularisation or readmission to hospital with heart failure. Hospitalization for AMI was defined as above and heart failure was defined as a hospital admission for which heart failure was the primary reason.
Statistical Analysis
Statistical analyses were performed on SPSS Version 12 (SPSS Inc, Chicago, Illinois). The continuous variables in the two independent groups were compared using the Mann Whitney U test. Spearman's correlations were performed and binary logistic regression analyses were conducted which, included baseline patient characteristics (age, sex, serum creatinine, Killip class, territory of AMI and whether the patient received thrombolysis or not) and peptide markers (including troponin I), to test the independent predictive power of the peptides above and below the median for ACO as defined above. In order to identify the independent predictors of ACO the Cox proportional hazard analyses was used. Kaplan Meier survival curves were generated to visualise the relationship between the peptides NT-BNP and UII and the composite endpoints. To compare the predictive value of NT-BNP and UII, receiveroperating characteristic (ROC) curves were generated and the area under the curves (AUC) was calculated. A p value below 0.05 was deemed to be statistically significant. Power calculations suggested that a standardised difference of log transformed UII levels of 0.6 (SD estimated at 0.5) could be detected with a power of 80% at p <0.05 with a sample size of 90. A larger number was recruited in case some patients were lost to follow-up.
Results
Patient Characteristics
The demographic features of the patient population are shown in Table 1 . Median length of follow-up was 102 days with a range of 0-189 days. Of the patients enrolled, 64.8 % received thrombolysis during the index admission. No patient was lost to follow-up. During follow-up, 14 (10.8%) patients died, 14 (10.8%) were readmitted with heart failure or AMI and 2 (1.6%) patients required urgent revascularisation in the form of percutaneous coronary intervention.
Echocardiographic data was available for 117 (90.7%) of the 129 patients and done at median of 3.5 days (range 2-5). 10 echocardiograms were unanalysable and 2 patients did not receive an echocardiogram.
UII levels in patients and controls
Plasma levels of UII in patients with AMI ranged from 0.29-34.50 fmol/ml. Median level over the 5 days was 1.40 fmol/ml. These levels were significantly higher than those observed in the 6 control subjects (median 0.42 fmol/ml, range 0.29-4.27 fmol/ml; p=0.012). UII levels were not 
Relationship between UII and echocardiographic parameters
For the whole population, mean LVWMI was 1. Using a Cox proportional hazards model, UII (log rank 0.29, p=0.046) and NT-BNP (log rank 4.78, p=0.012) between 73-96 hr were independent predictors of the combined endpoint.
Kaplan-Meier survival analysis demonstrated that UII levels below the median were associated with poorer survival (log rank 5.72, p=0.022, figure 4 ). Conversely NT-BNP levels above the median were associated with poorer survival over the study period (log rank 8.93, p= 0.003, figure 5 ).
NT-BNP above the median was also related to death and heart failure (log rank 4.85, p=0.028, log rank 5.26, p=0.022 respectively, figure 6, 7). UII did not show such a relationship to death or heart failure (log rank 0.3, p=0.582, log rank 0.38, p=0.538 respectively, graphs not shown).
Discussion
Current methods of predicting risk of cardiovascular events in patients with AMI rely on clinical criteria, electrocardiographic criteria and echocardiography. These methods however are not very accurate at predicting adverse events. The use of biomarkers may be more informative with regards to risk of adverse events following an AMI.
This is the first study reporting plasma levels of UII in the acute phase of patients with AMI.
Patients with AMI had significantly higher median UII levels than control subjects. Plasma UII levels in our control subjects were slightly higher than those reported by Richards et al (which employed ethanol precipitation of plasma and a radioimmunoassay) [12] , but are similar to those values in a previous study by Ng et al (which employed C 18 extracts of plasma and immunoluminometric assay) [8] . There are numerous biological and methodological factors that may influence the absolute values of the assay results. Some of the differences may be due to subject selection or assay antibody performance.
In our study UII did not show any correlation with peak troponin I and LVWMSI. This lack of correlation suggests that UII is not a marker of myocardial necrosis. UII may play an important role in the pathophysiology of atherosclerosis [13] . UII was found to be upregulated in the different leucocytes subpopulations, which propagate this disease state. Lymphocytes were found to be the largest producers of UII [13] . In contrast monocytes and macrophages were the largest producers of the UII receptor GPR14 [13] . This has also been borne out in a recent study showing elevated levels of UII in endothelial, myointimal and medial smooth muscle cells of atherosclerotic human coronary arteries [14] . Therefore UII may have a role in the pathophysiology of atherosclerosis.
This study is the first to report that plasma levels of UII were significantly lower in patients incurring combined endpoints of death, heart failure, MI or the need for urgent revascularisation than in those patients spared of these events. This paradoxical response to disease severity has been documented in the past for peptides such as myotrophin and urocortin [15, 16] . It is inferred that elevated levels of UII in AMI may produce transient improvements in cardiac performance associated with a better prognosis. Our study demonstrated for the first time that plasma levels of UII independently predicted adverse outcome in patients presenting with AMI. In this present study we compared the utility of the natriuretic peptide NT-BNP in combination with UII for the prediction of composite endpoints. Although NT-BNP is a powerful maker of adverse events, both NT-BNP and UII are complementary and interactive prognostic indicators. The predictive value of the natriuretic peptide was enhanced markedly and complemented by plasma UII. Cox proportional hazard modelling confirmed these findings with UII and NT-BNP each independently predictive of combined endpoints. Our study suggests that UII measured at 73-96 hours rather than earlier in the acute phase, is a stronger predictor of poor clinical outcomes.
In this present research the survival analyses demonstrated that plasma levels of UII, below the median were associated with a poorer survival and increased likelihood of ACO. This suggests that those patients who fail to mount an adequate UII response in AMI have a poor prognosis, this is in contrast to our and others' results for NT-BNP [2, 17, 18] and for numerous other peptides studied in the immediate post infarct period [2, 19, 20] . Elevated levels of UII may be cardioprotective at a time when the patient's cardiovascular system is most vulnerable. UII may be acting as a peripheral vasodilator post AMI acting to unload the infarcted myocardium, UII has previously been shown to have both a positive inotropic [5] and a peripheral vasodilator effect in resistance vessels [6] . This would then offer a possible explanation for the principal findings of our report in so far as those patients who fail to mount an adequate UII response then have a worse clinical outcome. Together UII and NT-BNP offer a practical early post-myocardial infarction risk stratification, which is more precise than either marker used alone. Further larger studies are required to validate these findings. UII or other analogues that are GPR14 agonists may also be a possible target for future therapy in patients who have had an AMI, similar to the therapeutic use of natriuretic peptides in heart failure [21] .
Limitations
There are a number of limitations to this study. Our study consisted of a relatively small number of patients and events. Despite this limitation, our study reinforced previous findings relating to NT-BNP and adverse patient outcomes and established new relationships between the novel peptide UII and event-free survival. Further studies are required to investigate the long-term pattern of secretion after AMI, to understand whether UII has a beneficial or detrimental role to play in this disease process. 
